Title:
Anticancer drug development guide : preclinical screening, clinical trials, and approval / edited by Beverly A. Teicher.
Cancer drug discovery and development.
Author:
Teicher, Beverly A., 1952-
General Notes:
Includes bibliographical references and index.
Pt. 1. In vitro methods -- High-volume screening -- The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985-1995 -- Human tumor screening -- Pt. 2. In vivo methods -- Murine L1210 and P388 leukemias -- In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery -- Human tumor xenograft models in NCI drug development -- Fertile seed and rich soil: the development of clinically relevant models of human cancer by surgical orthotopic implantation of intact tissue -- Preclinical models for high-dose therapy -- Models for minimal residual tumor -- Spontaneously occuring tumors in companion animals as models for drug development -- Pt. 3. Clinical testing -- Working with the National Cancer Institute -- Phase I trial design and methodology -- Phase II clinical trials in oncology -- Drug development in Europe -- The phase III cancer clinical trial -- FDA role in cancer drug development and requirements for approval.
Publisher:
Humana Press,
Publication Place:
Totowa, N.J. :
ISBN:
0896034615 (alk. paper)
0896034607 (alk. paper)
Subject:
Antineoplastic agents -- Development.
Antineoplastic Agents -- standards.
Drug Approval.
Drug Screening.
Series:
Cancer drug discovery and development.
Contents:
Pt. 1. In vitro methods -- High-volume screening -- The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985-1995 -- Human tumor screening -- Pt. 2. In vivo methods -- Murine L1210 and P388 leukemias -- In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery -- Human tumor xenograft models in NCI drug development -- Fertile seed and rich soil: the development of clinically relevant models of human cancer by surgical orthotopic implantation of intact tissue -- Preclinical models for high-dose therapy -- Models for minimal residual tumor -- Spontaneously occuring tumors in companion animals as models for drug development -- Pt. 3. Clinical testing -- Working with the National Cancer Institute -- Phase I trial design and methodology -- Phase II clinical trials in oncology -- Drug development in Europe -- The phase III cancer clinical trial -- FDA role in cancer drug development and requirements for approval.
Physical Description:
xii, 311 p. : ill. ;
Publication Date:
c1997.
Log in
Help
